Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high‐titre inhibitor-Reference-Cited by-同舟云学术

Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high‐titre inhibitor

Published:2020-09-30 Issue:3 Volume:27 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Chen Yu‐Wei¹^ORCID,Chen Wei‐Jhong¹,Tseng Min‐Sheng¹²,Lo Hsu‐Chung¹,Shih Ming‐Yang³⁴^ORCID,Chen Yu‐Jen⁵,Lee Wen‐Lieng¹⁶,Wang Jiaan‐Der³⁴⁷^ORCID

Affiliation:

1. Cardiovascular Center Taichung Veterans General Hospital Taichung Taiwan

2. Division of Cardiology Department of Internal Medicine Kuang‐Tien General Hospital Taichung Taiwan

3. Center for Rare Disease and Hemophilia Taichung Veterans General Hospital Taichung Taiwan

4. Children's Medical Center Taichung Veterans General Hospital Taichung Taiwan

5. Department of Internal Medicine Taichung Veterans General Hospital Taichung Taiwan

6. Institute of Clinical Medicine National Yang‐Ming University School of Medicine Taipei Taiwan

7. Department of Industrial Engineering and Enterprise Information Tunghai University Taichung Taiwan

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14165

Reference10 articles.

1. Cardiovascular disease (CVD) in Canadians with haemophilia: Age-Related CVD in Haemophilia Epidemiological Research (ARCHER study)

2. Prevalence and risk factors of atherothrombotic events among 1054 hemophilia patients: A population-based analysis

3. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey

4. Coronary angiography with or without percutaneous coronary intervention in patients with hemophilia-Systematic review

5. Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab: a novel drug in hemophilia A prophylaxis – a narrative review;Expert Review of Hematology;2022-10-03

2. Current status of emicizumab using in clinical practice based on medical experience at Tokyo Medical University;Japanese Journal of Thrombosis and Hemostasis;2022